750,395 Drugs Made In America Acquisition II Corp. $DMII Shares Sold by Context Capital Management LLC

Context Capital Management LLC lowered its stake in Drugs Made In America Acquisition II Corp. (NASDAQ:DMII) by 50.0% in the third quarter, Holdings Channel.com reports. The institutional investor owned 749,605 shares of the company’s stock after selling 750,395 shares during the quarter. Context Capital Management LLC’s holdings in Drugs Made In America Acquisition II were worth $7,631,000 as of its most recent SEC filing.

Several other hedge funds have also modified their holdings of DMII. Kryger Capital LLC purchased a new stake in shares of Drugs Made In America Acquisition II during the 1st quarter valued at about $3,088,000. Healthcare of Ontario Pension Plan Trust Fund purchased a new position in Drugs Made In America Acquisition II in the 1st quarter worth approximately $19,960,000. Sona Asset Management US LLC boosted its holdings in Drugs Made In America Acquisition II by 66.7% in the 1st quarter. Sona Asset Management US LLC now owns 500,000 shares of the company’s stock worth $4,985,000 after acquiring an additional 200,000 shares during the period. Wealthspring Capital LLC purchased a new position in Drugs Made In America Acquisition II in the 3rd quarter worth approximately $4,063,000. Finally, SkyView Investment Advisors LLC acquired a new stake in Drugs Made In America Acquisition II in the second quarter valued at approximately $2,515,000.

Drugs Made In America Acquisition II Price Performance

NASDAQ:DMII opened at $10.23 on Wednesday. The firm has a 50-day moving average of $10.18 and a two-hundred day moving average of $10.08. Drugs Made In America Acquisition II Corp. has a 1-year low of $9.86 and a 1-year high of $10.33.

Drugs Made In America Acquisition II (NASDAQ:DMII) last announced its earnings results on Friday, August 14th. The company reported $0.07 earnings per share for the quarter.

Wall Street Analyst Weigh In

A number of analysts have recently issued reports on the stock. Wall Street Zen upgraded shares of Drugs Made In America Acquisition II to a “hold” rating in a research note on Saturday, October 24th. Weiss Ratings upgraded shares of Drugs Made In America Acquisition II from a “sell (e)” rating to a “sell (d-)” rating in a research note on Tuesday, September 1st. One analyst has rated the stock with a Sell rating. According to data from MarketBeat.com, the stock currently has an average rating of “Sell”.

About Drugs Made In America Acquisition II

Drugs Made In America Acquisition II is a special purpose acquisition company, or SPAC. It was formed to pursue a merger, acquisition or similar business combination with an operating company. The company has identified the pharmaceutical sector as its area of focus, with an emphasis on businesses connected to the production of drugs in the United States. It does not operate a drug-manufacturing or pharmaceutical business of its own.